Study on the relationship between clinical efficacy and prognostic effect of PD-1 inhibitors and lymphocyte subpopulation levels in elderly patients with advanced NSCLC
SUN Jun
ZHENG Jiehong
ZENG Yue
LI Hongmiao
Abstract：Objective To investigate the relationship between lymphocyte subpopulation levels and the clinical efficacy and prognosis of PD-1 inhibitors in elderly patients with advanced non-small cell lung cancer.Methods Seventy-five elderly patients with non-small cell lung cancer treated with PD-1 inhibitors in Jianhu People's Hospital from June 2021 to April 2023 were selected,and these 75 patients were divided into an effective group(n=60)and an ineffective group(n=15)according to whether PD-1 inhibitors were effective after 3 month of treatment.The long survival group(n=50,＞9 months)and the short survival group(n=25,＜9 months)were categorized according to progression-free survival(PFS,Median progression-free survival of 9 months).The clinical correlation of different efficacy groups and different prognosis groups were compared.Multi-factor Logistic regression analysis was used to predict the independent risk factors between the level of lymphocyte subpopulations in non-small cell lung cancer and the clinical efficacy and prognosis of PD-1 inhibitors.Results The PD-L1≥50%percentage,CD4+,NK cells and Tregs content were 51.67%,(35.08±9.45),(21.79±9.15)and(6.61±2.53)higher in the effective group than in the ineffective group 20.00%,(30.45±8.15),(17.78±7.56)and(5.18±1.06)(P＜0.05).The percentage of PD-L1≥50%,CD4+,NK cells and Tregs in the long survival group was 60.00%,(42.65±9.85),(23.68±9.86),(7.65±2.51)than in the short survival group 16.00%,(30.45±8.62),(18.42±8.96),(5.23±2.53)(P＜0.05).Multi-factor Logistic regression analysis showed that PD-L1,CD4+,NK cells and Tregs content were independent risk factors predicting clinical efficacy and prognosis of PD-1 inhibitors in non-small cell lung cancer(OR=3.540,0.443,0.474,0.491,P＜0.05).Conclusions By analyzing the lymphocyte subpopulation levels in elderly non-small cell lung cancer patients,it can guide the evaluation of the efficacy of PD-1 inhibitors.The levels of PD-L1,CD4+,NK cells,and Tregs are independent risk factors for predicting the clinical efficacy and prognosis of PD-1 inhibitors in non-small cell lung cancer.
Keywords：Non-small cell lung cancerLymphocytesPD-1 inhibitorClinical efficacyPrognosis
Publication Date：2024-08-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 372-376 )